Continuous delivery of dopaminergic drugs is an important treatment strategy to delay or reverse motor complications in Parkinson's disease (PD). Subcutaneous apomorphine (APO) infusion has been shown (in uncontrolled studies) to significantly reduce 'off' time and dyskinesia duration and severity, and long-term data show the beneficial effects persist for several years. There is some evidence that the maximum antidyskinetic effect of APO infusion may be attained when oral medications are reduced or discontinued, making monotherapy an important clinical goal. Recent studies demonstrate possible positive effects of APO infusion on the non-motor symptoms of PD. However, more trials are needed to assess the neuropsychiatric effects of this treatment. Moreover, randomised controlled trials are needed to compare APO infusion with best medical treatment and with other invasive treatments such as levodopa/carbidopa intestinal gel infusion and deep brain stimulation.
The management of the later stages of Parkinson's disease (PD) is greatly impacted by non-dopaminergic problems, such as dementia, depression and falls, and by the emergence of motor complications including motor fluctuations and dyskinesias. Motor fluctuations, such as 'wearing off' and unpredictable 'off', affect 30-100 % of patients. [1] [2] [3] [4] Dyskinesias can be 'on' (mostly choreatic), biphasic (often dystonic) or 'off' (dystonic). In the later stages of the disease, there is a loss of nigrostriatal neurons and a concomitant loss of storage capacity. Positron emission tomography imaging of dyskinetic and non-dyskinetic patients showed no difference in dopamine receptor binding, which suggests that dyskinesias are unlikely to be the effect of alterations in striatal dopamine receptor binding. 5 On the other hand, levodopa-induced changes in synaptic dopamine levels increase with the progression of PD. 6 These changes in synaptic dopamine concentration may be a factor in the emergence of peak-dose dyskinesias.
The pharmacokinetics of levodopa in the periphery, such as plasma half-life clearance, volume of distribution and maximum plasma concentrations, remain unchanged. 7 However, the absorption of oral levodopa, which takes place primarily in the duodenum, is affected as gastric emptying becomes more erratic. 8, 9 Pharmacodynamic postsynaptic striatal changes in gene expression, 10 neuropeptide formation 11 and discharge patterns of the basal ganglia 12 result in complex feedback loops. 13 Furthermore, non-dopaminergic factors such as glutamate, opioids and serotonin may be involved in the development of dyskinesia. 14 Sprouting of extrasynaptic dopaminergic terminals may also lead to dysregulated dopamine release. 15 One of the most important factors associated with the risk of motor complications is the degree of neuronal loss. In rats whose nigrostriatal system had been lesioned unilaterally by 6-hydroxydopamine, the level of levodopa-induced motor complications was related to lesion size. 16 In humans, if the first dose of levodopa is given at an advanced stage of the disease, motor complications may develop within a matter of weeks. 17 Furthermore, patients with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced chronic and severe parkinsonism developed dyskinesias or 'on-off' fluctuations within months of starting levodopa treatment. 14 Additional factors that contribute to a greater risk of motor complications include younger age at disease onset, 3, 18 lower bodyweight 19, 20 and genetic factors. 21 In addition to neuronal loss, several factors relating to the treatment strategy are important in the development of motor complications.
For example, the dose, 22 half-life and mode of delivery 23 of levodopa have a major impact on the emergence of motor complications.
Clinical studies show that initial dopamine agonist treatment delays motor complications [24] [25] [26] [27] and that the same drug (levodopa, apomorphine or lisuride) has different effects when administered continuously versus intermittently. [28] [29] [30] [31] [32] [33] These findings led to the concept that pulsatile receptor stimulation leads to the development of motor complications, while continuous drug delivery can delay or reverse motor complications. 
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Effects of Apomorphine Infusion on Motor Symptoms of Parkison's Disease
Apomorphine is a potent dopamine agonist. When compared with levodopa, the two drugs result in a similar degree of improvement in motor function. 34 The advantage of apomorphine is its fast onset of effect (typically <10 minutes). 34 A randomised, double-blind, placebo-controlled study showed that a single injection of apomorphine greatly improved motor function, but may also induce dyskinesias. 35 Subcutaneous injection of apomorphine is indicated for rescue from refractory 'off', unpredictable 'off', 'off' dystonia and painful 'off'.
APO infusion treatment was developed to continuously deliver apomorphine. In the 1990s, this treatment was mainly used in addition to ongoing oral treatment for the relief of 'off' periods. Studies have shown 65 % reductions in 'off' periods with APO infusion and oral treatment combined. [36] [37] [38] Most did not report effects on dyskinesias, although one study described a decline in dyskinesia, with a corresponding reduction in levodopa dosage from 1,260 to 280 mg/dl. 39 However, longer-term studies showed that the discontinuation of oral treatment, to achieve monotherapy with APO infusion, led to greater improvements in dyskinesias. 31, 32 In one study, patients were followed up for a mean of 33.8 months. 32 In both the monotherapy group and the polytherapy group, the duration of 'on' time increased (monotherapy group, 55 % to 83 %, p<0.005; polytherapy group, 53 % to 71 %, p=0.05). However, the mean maximum dyskinesia reduction was significantly higher in the monotherapy group than in the polytherapy group (64 % versus 30 %, p<0.001).
A small prospective study on the antidyskinetic effect of subcutaneous APO infusion used subjective and objective measures. 33 
Long-term Data
Long-term follow-up studies have confirmed improvements in motor function with APO infusion therapy. For example, a two-year follow-up study showed a 61 % decrease in dyskinesias and a 47 % reduction in 'off' time, 40 and another study showed a 50 % reduction in dyskinesia at two years and a 29 % reduction at five years. 41 Subcutaneous Apomorphine Infusion -An Update Other studies found less improvement with APO infusion. A Spanish multicentre retrospective study showed that 83 of 166 patients remained on APO infusion therapy at four years. 43 The reasons for terminating treatment included: lack of support (nine patients), lack of effect (eight patients), adverse effects (18 patients) -including skin changes (four patients), psychosis (nine patients), cognitive worsening (four patients) and haemolytic anaemia (one patient) -other illnesses (11 patients), loss to follow-up (four patients), switch to DBS (13 patients) and switch to levodopa/carbidopa intestinal gel (LCIG) infusion (four patients).
In patients who continued on APO infusion, the mean dose was 72 mg per day and the levodopa equivalent dose was reduced by 43 %. There was a marked reduction in 'off' duration (6.6 to 1.4 hours per day) and a 31 % reduction in dyskinesia severity.
Another multicentre study demonstrated that, at two years, 53 of 62 patients remained on APO infusion. 44 The reasons for terminating treatment were similar to the Spanish multicentre study: 43 adverse effects (eight patients), insufficient efficacy (four patients), death during the observation period (four patients), concomitant disease most likely not related to apomorphine (three patients),
insufficiently treated medication-induced paranoid psychosis probably related to apomorphine (one patient) and loss to follow-up (six patients). 44 The mean apomorphine dose was 78 mg per day and the levodopa equivalent dose was reduced by 32 %.
'Off' time was reduced by 79 % (see Figure 1 ) and there was a subjective improvement in dyskinesia in 33 % of patients and no difference in 52 % of patients. The treatment was rated as 'good' by 76 % of the patients.
In a proof-of-concept study, six PD patients with severe subcutaneous nodule formation as a result of long-term subcutaneous APO infusion were switched to intravenous apomorphine via a long-term in-dwelling venous catheter. 45 
Effects of Apomorphine Infusion on Non-motor Symptoms of Parkinson's Disease
A recent multicentre and comparative (but not randomised) study compared 17 PD patients on APO infusion and 17 patients eligible for apomorphine pump therapy who did not receive this treatment. 46 There were some differences between the APO and control groups at baseline: the control group had better scores in the UPDRS-III, the Non-Motor Symptoms Scale (NMSS) and Parkinson's Disease Questionnaire-8 (PDQ-8). At one year follow-up, levodopa equivalent dose was significantly reduced in the APO group
(1,078 ± 446 to 459 ± 282 mg, p<0.0001) and a large effect size of intervention was noted. This improvement was not observed in the untreated group. Moreover, the APO group showed significant Continuous Dopaminergic Stimulation in Focus improvements in UPDRS-III (p=0.0003), PDQ-8 (p=0.001) and NMSS total scores (p=0.0003) (see Table 1 ). In addition, APO infusion treatment was tolerated in patients with visual hallucinations, illusions and paranoid ideations, and resulted in significant improvements in specific non-motor symptoms (NMS) such as excessive sweating, nocturia, urgency of micturition and fatigue (see Table 2 ). The number needed to treat for improvement >1 standard error of the mean (SEM) in the APO infusion group was lower than 2 for UPDRS-III, NMSS and PDQ-8 total scores.
These results demonstrate the positive effects of APO infusion therapy on NMS, including a significant effect on mood/cognition (see Table 2 ). Other open-label, non-randomised studies had shown APO infusion therapy to have no effect on cognition. 42, [47] [48] [49] In comparison, DBS either had no effect on cognition 49 or led to a worsening. 42, 47, 48 Some studies have demonstrated improvements in depression with APO infusion treatment 49, 50 while others found no effect. 47, 48 Randomised studies are needed to study the effects of this treatment on NMS, in particular on neuropsychiatric problems.
Adverse Effects of Subcutaneous Apomorphine Infusion Therapy
Adverse effects of subcutaneous APO infusion therapy include dopaminergic effects (such as nausea, orthostatic hypotension, sleepiness, leg oedema), impulse control disorders and dopamine dysregulation. Another adverse effect is haemolytic anaemia, which is rare (≤2 %). 51 Mild-to-moderate skin reactions in the form of nodules (aseptic panniculitis) are the most common side effect. These may lead to absorption problems, but complications such as ulcerations and abscesses are rare.
Conclusions
There are now several treatment options for switching from intermittent to continuous dopaminergic stimulation (CDS) therapy.
Great improvements in motor and non-motor functioning can be achieved with CDS therapy, but limitations remain.
Dopaminergic stimulation is tonic under physiological conditions, but dopamine levels are not completely constant. In addition, little is known about how dopaminergic drugs stimulate the receptors. 52 Importantly, none of the available treatments influence the progression of the disease, which still leads to increased mortality and a considerable burden of disability. A follow-up study showed that among those patients who were still alive 20 years after PD diagnosis, 48 % were in a nursing home, 83 % had dementia, falls occurred in 87 % of them and incontinence in 71 %. 53 The real goal of research efforts is, therefore, to stop or reverse the progression of PD, but in the meantime continuous drug delivery remains an important clinical goal in an effort to reverse motor complications.
In order to achieve the full antidyskinetic potential of APO 
